Trevi Therapeutics, Inc. (TRVI): Price and Financial Metrics


Trevi Therapeutics, Inc. (TRVI): $1.85

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

TRVI Stock Price Chart Interactive Chart >

Price chart for TRVI

TRVI Price/Volume Stats

Current price $1.85 52-week high $4.68
Prev. close $1.85 52-week low $1.43
Day low $1.80 Volume 45,600
Day high $1.89 Avg. volume 51,131
50-day MA $2.23 Dividend yield N/A
200-day MA $2.49 Market Cap 111.08M

Trevi Therapeutics, Inc. (TRVI) Company Bio


Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.


TRVI Latest News Stream


Event/Time News Detail
Loading, please wait...

TRVI Latest Social Stream


Loading social stream, please wait...

View Full TRVI Social Stream

Latest TRVI News From Around the Web

Below are the latest news stories about TREVI THERAPEUTICS INC that investors may wish to consider to help them evaluate TRVI as an investment opportunity.

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2022 Earnings Call Transcript

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2022 Earnings Call Transcript March 16, 2023 Operator: Good afternoon and welcome to the Trevi Therapeutics Q4 and Year-End 2022 Earnings Conference Call. Please note this event is being recorded. Various remarks that management makes during this conference call about the company’s future expectations, plans and prospects constitute forward-looking statements […]

Yahoo | March 18, 2023

Q4 2022 Trevi Therapeutics Inc Earnings Call

Q4 2022 Trevi Therapeutics Inc Earnings Call

Yahoo | March 17, 2023

Trevi Therapeutics Announces Fourth Quarter and Year End 2022 Financial Results and Provides Business Update

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced financial results for the quarter and year ended December 31, 2022, as well as provided business updates.

Yahoo | March 16, 2023

Trevi Therapeutics to Report Q4 and Year End 2022 Financial Results and Provide a Corporate Update on March 16, 2023

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced that senior management will host a conference call and live audio webcast on Thursday, March 16, 2023, at 4:30 p.m. ET, to provide a corporate update and review the

Yahoo | March 9, 2023

Trevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio™ (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, today announced that on March 7, 2023, the United States Patent and Trademark Office ("USPTO") issued a notice of allowance for nalbuphine ER's method of treatment of chronic cough in IPF.

Yahoo | March 8, 2023

Read More 'TRVI' Stories Here

TRVI Price Returns

1-mo -19.21%
3-mo -4.15%
6-mo 14.91%
1-year -2.63%
3-year -41.08%
5-year N/A
YTD -4.15%
2022 146.74%
2021 -67.68%
2020 -35.47%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8442 seconds.